ASSEMBLY BIOSCIENCES INC
ASMBNASDAQTrading Snapshot
- Day Range
- $26.78 – $27.64
- 52-Week Range
- $20.23 – $39.71
- Volume
- $2.13B
- Avg Volume
- $2.24B
- Shares Outstanding
- 19.8M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $72M
- Last Q Revenue
- $8M
- P/E Ratio
- —
- P/S Ratio
- 7.5x
- EPS (TTM)
- $-1.29
- Dividend Yield
- —
Why Investors Own ASMB
- ✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ASSEMBLY BIOSCIENCES INC
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
